179 related articles for article (PubMed ID: 37464232)
21. Detailed characterization of PD-1/PD-L1 and CTLA4 expression and tumor-infiltrating lymphocytes in yolk sac tumors.
Zhang D; Xu H; Zhao C; Qin L; Wei R; Xi L; Li F
Hum Immunol; 2023 Oct; 84(10):534-542. PubMed ID: 37453913
[TBL] [Abstract][Full Text] [Related]
22. The immune microenvironment and expression of PD-L1, PD-1, PRAME and MHC I in salivary duct carcinoma.
Xu B; Jungbluth AA; Frosina D; Alzumaili B; Aleynick N; Slodkowska E; Higgins K; Ho A; Morris L; Ghossein R; Katabi N
Histopathology; 2019 Nov; 75(5):672-682. PubMed ID: 31237963
[TBL] [Abstract][Full Text] [Related]
23. Programmed death-ligand 1 expression in the immune compartment of colon carcinoma.
Yılmaz O; Pankaj A; Neyez A; Rickelt S; Taylor M; Lang ER; Leijsen L; Dinaux A; Shroff SG; Crotty R; Zhang ML; Cerda S; Zhao Q; Ferrone C; Ting DT; Patil DT; Yilmaz O; Berger D; Deshpande V
Mod Pathol; 2022 Nov; 35(11):1740-1748. PubMed ID: 35773332
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic implications of immune-profiling and EGFR expression in salivary gland carcinoma.
Guazzo E; Cooper C; Wilkinson L; Feng S; King B; Simpson F; Porceddu S; Panizza B; Coward JIG
Head Neck; 2021 Mar; 43(3):768-777. PubMed ID: 33169486
[TBL] [Abstract][Full Text] [Related]
25. Tumor microenvironment and its clinicopathological and prognostic associations in surgically resected cutaneous angiosarcoma.
Bi Y; Ge L; Ren X; Pang J; Zhao Y; Liang Z
Clin Transl Oncol; 2022 May; 24(5):941-949. PubMed ID: 35064455
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous Expression of PD-1 and PD-L1 in Peripheral and Central Immune Cells and Tumor Cells in the Benign and Malignant Salivary Gland Tumors Microenvironment.
Gerdabi S; Asadian F; Kiani R; Khademi B; Haghshenas MR; Erfani N
Head Neck Pathol; 2023 Mar; 17(1):178-192. PubMed ID: 36169795
[TBL] [Abstract][Full Text] [Related]
27. Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response.
Shin SJ; Kim SY; Choi YY; Son T; Cheong JH; Hyung WJ; Noh SH; Park CG; Kim HI
Oncologist; 2019 Sep; 24(9):e835-e844. PubMed ID: 30894409
[TBL] [Abstract][Full Text] [Related]
28. HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1.
Jing CY; Fu YP; Yi Y; Zhang MX; Zheng SS; Huang JL; Gan W; Xu X; Lin JJ; Zhang J; Qiu SJ; Zhang BH
J Immunother Cancer; 2019 Mar; 7(1):77. PubMed ID: 30885276
[TBL] [Abstract][Full Text] [Related]
29. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Categorizing Gastric Carcinoma by PD-L1 Expression and Tumor Infiltrating Lymphocytes.
Noh BJ; Kim JH; Eom DW
Ann Clin Lab Sci; 2018 Nov; 48(6):695-706. PubMed ID: 30610038
[TBL] [Abstract][Full Text] [Related]
31. PD1/PD-L1 Expressions in Plasmablastic Lymphoma with Clinicopathological Correlation.
Rosado FG; Coberly J; Gupta A; John G; Naina H; Koduru P; Chen W
Ann Clin Lab Sci; 2021 Mar; 51(2):174-181. PubMed ID: 33941556
[TBL] [Abstract][Full Text] [Related]
32. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
33. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer.
Morihiro T; Kuroda S; Kanaya N; Kakiuchi Y; Kubota T; Aoyama K; Tanaka T; Kikuchi S; Nagasaka T; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Sci Rep; 2019 Mar; 9(1):4633. PubMed ID: 30874607
[TBL] [Abstract][Full Text] [Related]
34. Dedifferentiated Endometrial Carcinoma Could be A Target for Immune Checkpoint Inhibitors (Anti PD-1/PD-L1 Antibodies).
Ono R; Nakayama K; Nakamura K; Yamashita H; Ishibashi T; Ishikawa M; Minamoto T; Razia S; Ishikawa N; Otsuki Y; Nakayama S; Onuma H; Kurioka H; Kyo S
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370215
[TBL] [Abstract][Full Text] [Related]
35. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of PD-L1, tumor-infiltrating lymphocytes, and CD8+ and FOXP3+ immune cells in HER2-positive breast cancer treated with neoadjuvant therapies.
Zhao J; Meisel J; Guo Y; Nahta R; Hsieh KL; Peng L; Wei Z; O'Regan R; Li X
Breast Cancer Res Treat; 2020 Oct; 183(3):599-606. PubMed ID: 32715443
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of immune checkpoints in the tumour-stromal microenvironment of sebaceous gland carcinoma.
Singh L; Singh MK; Rizvi MA; Pushker N; Bakhshi S; Sen S; Kashyap S
Br J Ophthalmol; 2021 Jan; 105(1):48-56. PubMed ID: 32277010
[TBL] [Abstract][Full Text] [Related]
38. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
39. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
40. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact.
Kim JY; Kim WG; Kwon CH; Park DY
Gastric Cancer; 2019 Nov; 22(6):1164-1175. PubMed ID: 31152268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]